SEC ownership of Athenex, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001300699.

Comparable stake leader

Johnson Yiu Nam Lau

Disclosed value leader

Johnson Yiu Nam Lau

Comparable rows

0/19

Latest evidence

05 May 2023

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 1 signal
Latest parsed ownership date
05 May 2023
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001300699
Issuer location
Buffalo, NY

Ownership snapshot

Top shareholders of Athenex, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Johnson Yiu Nam Lau
Disclosed value leader
Johnson Yiu Nam Lau
Comparable rows
0/19
Latest evidence
05 May 2023
3/4/5 Highest disclosed value: $405,210 19 rows are not safely comparable across share classes. Showing 1-8 of 19 holder rows.

Quick read

Johnson Yiu Nam Lau has the largest disclosed position value at $405.2K.

0 of 19 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Johnson Yiu Nam Lau's linked filing trail.
Disclosed position value Top 5
Johnson Yiu Nam Lau $405.2K
Jeffrey Yordon $334.5K
Manson Fok $204K
William Wei Zuo $194.3K
Daniel Lang $111K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-8 of 19 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Johnson Yiu Nam Lau
3/4/5
CEO and Chairman of the Board, Director
mixed-class rows
$405,210
318,819 shares
mixed-class rows
05 May 2023
Jeffrey Yordon
3/4/5
COO, and President, Athenex Pharmaceutical Division.
mixed-class rows
$334,482
433,443 shares
mixed-class rows
03 Aug 2022
Manson Fok
3/4/5
Director
mixed-class rows
$203,972
153,350 shares
mixed-class rows
21 Apr 2023
William Wei Zuo
3/4/5
President, China Division
mixed-class rows
$194,321
167,883 shares
mixed-class rows
03 Aug 2021
Daniel Lang
3/4/5
Pres Cell Therapy, VP Corp Dev
mixed-class rows
$110,962
319,090 shares
mixed-class rows
16 Sep 2022
Rudolf Kwan
3/4/5
EVP, Chief Medical Officer
mixed-class rows
$67,750
56,191 shares
mixed-class rows
05 May 2023
Jinn Wu
3/4/5
Director
mixed-class rows
$47,331
35,552 shares
mixed-class rows
21 Apr 2023
Jordan Kanfer
3/4/5
Director
mixed-class rows
$23,237
34,586 shares
mixed-class rows
03 Aug 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 09 Jul 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to Athenex, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
Johnson Yiu Nam Lau
Net 12M change
$0
Latest report
05 May 2023
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Johnson Yiu Nam Lau CEO and Chairman of the Board, Director $405,210 Mixed 05 May 2023
Jeffrey Yordon COO, and President, Athenex Pharmaceutical Division. $334,482 Mixed 03 Aug 2022
Manson Fok Director $203,972 Mixed 21 Apr 2023
William Wei Zuo President, China Division $194,321 Mixed 03 Aug 2021
Daniel Lang Pres Cell Therapy, VP Corp Dev $110,962 Mixed 16 Sep 2022
Rudolf Kwan EVP, Chief Medical Officer $67,750 Mixed 05 May 2023
Jinn Wu Director $47,331 Mixed 21 Apr 2023
Jordan Kanfer Director $23,237 Mixed 03 Aug 2022
Benson Kwan Hung Tsang Director $23,011 Mixed 21 Apr 2023
John Vierling Director $16,767 Mixed 21 Apr 2023
Kim Campbell Director $13,600 Mixed 03 Aug 2021
Stephanie A. Davis Director $10,900 Mixed 21 Apr 2023
Simon Pedder Officer $7,222 Mixed 03 Aug 2021
Michael Smolinski Chief Scientific Officer $7,035 Mixed 16 Nov 2021
Robert J. Spiegel Director $6,245 Mixed 21 Apr 2023
Timothy DeVere Cook Chief Business and Commercial Officer, Proprietary Drugs $5,630 Mixed 05 May 2023
Joe Annoni Chief Financial Officer $510 Mixed 22 Feb 2023
Steven J. Adams Interim Chief Acct Officer Mixed 03 Aug 2021
Teresa Brophy Bair General Counsel, SVP Admin. Mixed 03 Aug 2021

Recent insider transactions for Athenex, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
No insider transactions were found in the last 12 months for this issuer.
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .